Updated on: June 18, 2025 / 8:07 PM EDT / CBS News The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV. The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based on data from clinical…
The FDA recently approved dolutegravir for the treatment of HIV. Researchers at UC San Diego contributed to the research that made this new approval possible. Previously, dolutegravir was approved only for adults and children aged four weeks and older. The…
Posted by cfelixcpa | Apr 28, 2025 | SF STAT! | 0 | Join us for “Breaking Barriers: A Community Symposium on PrEP Access & HIV Prevention” happening on Tuesday, May 6, 2025. The Health Council of South Florida, Inc. (HCSF) is excited to bring together leading experts for a…
– Submission Supported By Clinical Profile of Lenacapavir, Which Demonstrated High Efficacy in HIV Prevention Across Two Clinical Trials – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA)…
The Lagos State AIDS Control Agency has warned food-sector employers against excluding workers living with HIV on food-safety grounds, saying the virus cannot be transmitted through preparing, handling or serving food. LSACA made the position known at a sensitisation meeting…
Interdisciplinary Training Grant in AIDS Research Your gift powers excellence in research and education to advance public health. The Biostatistics/Epidemiology Training Grants in AIDS prepares graduate students and postdoctoral fellows for biostatistical and epidemiological research directed against the HIV…
CROWN is an international, randomised, open-label study designed to evaluate whether people living with HIV-1 who have detectable virus despite a history of daily oral ART can directly initiate CAB + RPV LA, administered six times a year, and achieve viral…
European AIDS Treatment Group [Press release] ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia ViiV Healthcare announced the phase IIIb CROWN study met its primary…
Long-acting cabotegravir plus rilpivirine (Cabenuva) achieved superior viral suppression vs daily oral antiretroviral therapy at 6months in treatment-experienced people with HIV and detectable viremia in the phase 3b CROWN trial. The regimen is currently approved as Cabenuva in the US, and as…
Published Oct 5, 2026 Convenient HIV testing at three gay bars in New Orleans is coming to a close, drawing criticism from LGBTQ+ community members and patrons who have relied on the service, according to WDSU. And honestly, it is easy to…
Preventing HIV: PrEP pills and lenacapavir injections, HIV testing campaigns and vaccine research.
An article joins this feed when it matches these terms. Each one is also a search of its own.